Canadian Pharmacy Discourages the Use of New Blood Thinner Drug

Jun 19
09:08

2012

Remcel Mae P. Canete

Remcel Mae P. Canete

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner, Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome.

mediaimage

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner,Canadian Pharmacy Discourages the Use of New Blood Thinner Drug Articles Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome.  To buy Warfarin is still one of the safest and most effective moves when it comes to blood thinning medications. 

Xarelto (rivaroxaban) is one of a new class of blood thinners that has been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring. The effectiveness of generic Warfarin also can be altered by certain foods and other medications. Xarelto is already approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery. 

"What is not reflected in the sponsor's analysis are minor bleeding events," FDA reviewer Dr. Karen Hicks wrote in the briefing documents. "While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved." 

"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention," Hicks wrote. "Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks." 

In research presented at the American Stroke Association's International Stroke Conference in New Orleans in February, Australian doctors followed more than 14,000 people who took either Xarelto or warfarin for a median of two years. Of those patients, 136 had bleeding in the brain. 

People who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found. Canadian pharmacy encourages doctors and patients to decide wisely when it comes to choosing the right drug. 

Blood is a specialized bodily fluid in animals that delivers necessary substances such as nutrients and oxygen to the cells and transports metabolic waste products away from those same cells.

In vertebrates, it is composed of blood cells suspended in a liquid called blood plasma. Plasma, which constitutes 55% of blood fluid, is mostly water (92% by volume), and contains dissipated proteins, glucose, mineral ions, hormones, carbon dioxide (plasma being the main medium for excretory product transportation), and blood cells themselves. Albumin is the main protein in plasma, and it functions to regulate the colloidal osmotic pressure of blood. The blood cells are mainly red blood cells (also called RBCs or erythrocytes) and white blood cells, including leukocytes and platelets. The most abundant cells in vertebrate blood are red blood cells. These contain hemoglobin, an iron-containing protein, which facilitates transportation of oxygen by reversibly binding to this respiratory gas and greatly increasing its solubility in blood. In contrast, carbon dioxide is almost entirely transported extracellularly dissolved in plasma as bicarbonate ion.